ClinicalTrials.gg

TargetBeta

CD19

CD19 molecule · CD molecules

44 programs in company-led studies act on CD19, from 34 companies: 10 in phase 3, 2 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (33 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyFurthest phaseStudiesAlso acts onRead from
inebilizumabruleAmgenphase 41911 running–NCIt
blinatumomabruleAmgenphase 4297 runningCD3EChEMBL
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 31212 runningTNFRSF17a judged reading
surovatamigAstraZenecaphase 31010 runningCD3Ea judged reading
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 388 runningCD3Ea judged reading
Autologous Anti-CD19 CAR-T Cells CABA-201ruleCabaletta Biophase 365 running–NCIt
zolacabtagene autoleucelBristol-Myers Squibbphase 365 running–a judged reading
obexelimabZenas BioPharma (USA)phase 374 runningFCGR2Ba judged reading
axicabtagene ciloleucelruleGilead Sciencesphase 3103 running–ChEMBL
lisocabtagene maraleucelruleBristol-Myers Squibbphase 3103 running–ChEMBL
Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753ruleGilead Sciencesphase 322 running–NCIt
rondecabtagene autoleucelruleLyell Immunopharmaphase 322 runningMS4A1NCIt
rapcabtagene autoleucelNovartisphase 287 running–the company's pipeline
zamtocabtagene autoleucelruleMiltenyi Biomedicinephase 287 runningCD4, CD8A, MS4A1NCIt
obecabtagene autoleucelruleAutolusphase 255 running–NCIt
YK012ruleExcyte Biopharmaphase 255 runningCD3Ethe studies' text
budoprutugruleClimb Biophase 284 running–the studies' text
Allogeneic CRISPR-Cas9 Engineered Anti-CD19 CAR T-cells CTX112ruleCRISPR Therapeuticsphase 244 running–NCIt
Autologous Anti-CD19/CD20 CAR-T Cells KITE-363ruleGilead Sciencesphase 233 runningMS4A1NCIt
belacabnagene franleucelruleNkartaphase 233 runningIL15NCIt
iPSC-derived Allogeneic Anti-CD19 1XX-CAR T-cells FT819ruleFate Therapeuticsphase 233 running–NCIt
anbalcabtagene autoleucelruleCurocellphase 222 running–NCIt
GSK5926371GlaxoSmithKlinephase 222 runningCD3E, MS4A1the company's pipeline
prizloncabtagene autoleucelruleAbelZetaphase 222 runningMS4A1NCIt
Allogeneic Anti-CD19/CD20 CAR T-cells AVC-203ruleAvenCell Therapeuticsphase 211 runningMS4A1NCIt
Autologous Anti-CD19 CAR-expressing T LymphocytesruleBeijing Biotechphase 211 running–NCIt
CRT-402ruleMyeloid Therapeuticsphase 211 running–the studies' text
CT204V-CD19 × CD20ruleAstraZenecaphase 211 runningMS4A1the studies' text
QEL-005ruleQuell Therapeuticsphase 211 running–the studies' text
YTS109ruleChina Immunotech (Beijing) Biotechnologyphase 186 running–the studies' text
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312ruleCytoCaresphase 144 runningCD28, CD3ENCIt
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978ruleCullinan Therapeuticsphase 143 runningCD3ENCIt
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 133 runningCD2, CD3Ethe company's pipeline
BCMA-CD19 Compound CAR T CellsruleiCell Gene Therapeuticsphase 133 runningTNFRSF17NCIt
Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31AbbViephase 122 running–the company's pipeline
ABBV-519AbbViephase 111 running–the company's pipeline
ARM011ruleTriArm Therapeutics (Taiwan)phase 111 running–the studies' text
ATG-201ruleAntengene Biologicsphase 111 runningCD3Ethe studies' text
CPTX2309AbbViephase 111 running–the company's pipeline
HB2198ruleHinge Biophase 111 runningMS4A1the studies' text
KT501ruleKali Therapeuticsphase 111 runningCD3Ethe studies' text
KT502ruleKali Therapeuticsphase 111 runningCD3Ethe studies' text
ORN252ruleEli Lillyphase 111 running–the studies' text
vispacabtagene regedleucelruleCaribou Biosciencesphase 110 running–NCIt

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.